SK1602001A3 - 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use - Google Patents

2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use Download PDF

Info

Publication number
SK1602001A3
SK1602001A3 SK160-2001A SK1602001A SK1602001A3 SK 1602001 A3 SK1602001 A3 SK 1602001A3 SK 1602001 A SK1602001 A SK 1602001A SK 1602001 A3 SK1602001 A3 SK 1602001A3
Authority
SK
Slovakia
Prior art keywords
alkyl
carbon atoms
group
aromatic
independently selected
Prior art date
Application number
SK160-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Fumitaka Ito
Hirohide Noguchi
Hiroshi Kondo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK1602001A3 publication Critical patent/SK1602001A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK160-2001A 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use SK1602001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06
PCT/IB1999/001239 WO2000008013A2 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists

Publications (1)

Publication Number Publication Date
SK1602001A3 true SK1602001A3 (en) 2002-09-10

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
SK160-2001A SK1602001A3 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use

Country Status (44)

Country Link
US (1) US6172067B1 (tr)
EP (1) EP1102762B1 (tr)
JP (1) JP3367945B2 (tr)
CN (1) CN1317968A (tr)
AP (1) AP2001002063A0 (tr)
AR (1) AR018686A1 (tr)
AT (1) ATE227716T1 (tr)
AU (1) AU749166B2 (tr)
BG (1) BG105301A (tr)
BR (1) BR9912778A (tr)
CA (1) CA2339621C (tr)
CZ (1) CZ2001397A3 (tr)
DE (1) DE69903953T2 (tr)
DK (1) DK1102762T3 (tr)
EA (1) EA200100104A1 (tr)
EE (1) EE200100075A (tr)
ES (1) ES2185357T3 (tr)
GE (1) GEP20033000B (tr)
GT (1) GT199900125A (tr)
HK (1) HK1040188A1 (tr)
HN (1) HN1999000105A (tr)
HR (1) HRP20010089B1 (tr)
HU (1) HUP0103567A3 (tr)
ID (1) ID27212A (tr)
IL (1) IL141029A0 (tr)
IS (1) IS5812A (tr)
MA (1) MA26659A1 (tr)
NO (1) NO20010603L (tr)
NZ (1) NZ509299A (tr)
OA (1) OA11590A (tr)
PA (1) PA8477701A1 (tr)
PE (1) PE20000868A1 (tr)
PL (1) PL346211A1 (tr)
PT (1) PT1102762E (tr)
SI (1) SI1102762T1 (tr)
SK (1) SK1602001A3 (tr)
SV (1) SV1999000099A (tr)
TN (1) TNSN99142A1 (tr)
TR (1) TR200100403T2 (tr)
TW (1) TW513424B (tr)
UY (1) UY25659A1 (tr)
WO (1) WO2000008013A2 (tr)
YU (1) YU8201A (tr)
ZA (1) ZA200100900B (tr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1122257B1 (en) * 2000-01-05 2005-10-12 Pfizer Inc. Benzimidazole compounds as ORL1-receptor agonists
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
JP4155029B2 (ja) * 2000-11-15 2008-09-24 萬有製薬株式会社 ベンズイミダゾール誘導体
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
NZ551453A (en) 2001-04-18 2008-02-29 Euro Celtique Sa Nociceptin analogs for the treatment of pain
HUP0402510A3 (en) * 2001-04-18 2012-08-28 Euro Celtique Sa Nociceptin analogs and pharmaceutical compositions containing them
DK1385514T5 (da) 2001-04-18 2009-03-09 Euro Celtique Sa Spiroinden- og spiroindanforbindelser
ES2312584T3 (es) 2001-04-18 2009-03-01 Euro-Celtique S.A. Compuestos de espiropirazol.
AU2002338424B2 (en) * 2001-04-18 2005-04-21 Euro-Celtique S.A. Benzimidazolone compounds
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
AU2003220886A1 (en) 2002-03-29 2003-10-13 Mitsubishi Pharma Corporation Remedy for sleep disturbance
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
US8067603B2 (en) 2003-09-25 2011-11-29 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
EP1810677A1 (en) * 2004-10-08 2007-07-25 Takeda Pharmaceutical Company Limited Receptor function regulating agent
WO2006074991A1 (en) 2005-01-11 2006-07-20 Neurosearch A/S Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
US20090239880A1 (en) * 2006-07-03 2009-09-24 Ulrik Svane Sorensen Combinations of monoamine reuptake inhibitors and potassium channel activators
KR101227072B1 (ko) 2007-01-16 2013-01-29 시오노기세이야쿠가부시키가이샤 Orl-1 리간드로서의 헤테로시클릭-치환 피페리딘
BRPI0815327A2 (pt) * 2007-08-31 2015-12-15 Purdue Pharma Lp "compostos de piperidina do tipo quinoxalina substituída e os usos destes"
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
PE20140102A1 (es) 2008-07-21 2014-02-06 Purdue Pharma Lp Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
MX2013001313A (es) 2010-08-05 2013-06-13 Amgen Inc Compuestos de bencimidazol y azabencimidazol que inhiben la cinasa del linfoma anaplasico.
US9169203B2 (en) 2012-01-06 2015-10-27 Novus International, Inc. Sulfoxide-based surfactants
AU2013216832B2 (en) 2012-02-09 2016-09-22 Novus International Inc. Heteroatom containing cyclic dimers
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
BR112015000494A2 (pt) 2012-07-12 2017-06-27 Novus Int Inc matriz e composições da camada para a proteção dos biotivos
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014153529A1 (en) 2013-03-22 2014-09-25 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
EP3922630A1 (en) * 2014-03-20 2021-12-15 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
CN108291055B (zh) 2015-11-12 2021-07-06 诺华丝国际股份有限公司 作为溶剂的含硫化合物
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
EP1241259A1 (en) 1995-08-15 2002-09-18 Universite Libre De Bruxelles Peptide having pronociceptive properties
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
US6180649B1 (en) * 1996-04-19 2001-01-30 Nerosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP0813065A3 (en) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
EP0829481A1 (en) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
JP4366532B2 (ja) 1997-05-30 2009-11-18 萬有製薬株式会社 2−オキソイミダゾール誘導体
AU8334298A (en) 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
BG105301A (en) 2001-12-29
YU8201A (sh) 2003-07-07
ATE227716T1 (de) 2002-11-15
PA8477701A1 (es) 2000-09-29
NZ509299A (en) 2003-05-30
CN1317968A (zh) 2001-10-17
GT199900125A (es) 2001-01-27
EA200100104A1 (ru) 2001-08-27
IS5812A (is) 2001-01-16
IL141029A0 (en) 2002-02-10
UY25659A1 (es) 2000-02-23
HUP0103567A2 (hu) 2002-02-28
SV1999000099A (es) 2000-09-05
BR9912778A (pt) 2001-09-25
AP2001002063A0 (en) 2001-03-31
OA11590A (en) 2004-08-18
JP3367945B2 (ja) 2003-01-20
AU749166B2 (en) 2002-06-20
TNSN99142A1 (fr) 2005-11-10
DE69903953D1 (de) 2002-12-19
HK1040188A1 (zh) 2002-05-31
PT1102762E (pt) 2003-02-28
NO20010603D0 (no) 2001-02-05
CA2339621C (en) 2005-04-05
EE200100075A (et) 2002-06-17
DK1102762T3 (da) 2002-12-16
PL346211A1 (en) 2002-01-28
DE69903953T2 (de) 2003-03-27
TR200100403T2 (tr) 2001-07-23
PE20000868A1 (es) 2000-08-31
AU4385999A (en) 2000-02-28
EP1102762B1 (en) 2002-11-13
WO2000008013A2 (en) 2000-02-17
CZ2001397A3 (cs) 2002-05-15
NO20010603L (no) 2001-04-05
WO2000008013A3 (en) 2000-03-23
GEP20033000B (en) 2003-06-25
ZA200100900B (en) 2002-08-28
HUP0103567A3 (en) 2003-01-28
JP2002522431A (ja) 2002-07-23
US6172067B1 (en) 2001-01-09
ES2185357T3 (es) 2003-04-16
TW513424B (en) 2002-12-11
HN1999000105A (es) 2000-11-11
MA26659A1 (fr) 2004-12-20
CA2339621A1 (en) 2000-02-17
AR018686A1 (es) 2001-11-28
ID27212A (id) 2001-03-08
HRP20010089A2 (en) 2002-02-28
SI1102762T1 (en) 2003-04-30
HRP20010089B1 (en) 2003-04-30
EP1102762A2 (en) 2001-05-30

Similar Documents

Publication Publication Date Title
SK1602001A3 (en) 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use
US6423725B1 (en) 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
JP3276111B2 (ja) Orl1−レセプターアゴニストとしての2−ベンズイミダゾリルアミン化合物
US6294555B1 (en) 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
EP1499596B1 (en) Muscarinic antagonists
WO2000009506A1 (fr) Derives de 1h-imidazopyridine
CA2330092C (en) Benzimidazole compounds as orl1-receptor agonists
CA2444595A1 (en) Benzimidazolone derivatives
JP2007055940A (ja) ピラゾロピリミジン誘導体
JPWO2002040019A1 (ja) ベンズイミダゾール誘導体
JP2009511552A (ja) 置換1−アミノ−フタラジン誘導体、これらの調製およびこれらの治療的使用
WO2007111227A1 (ja) アシルアミノピペリジン化合物
IL161699A (en) Piperidine derivatives, process for their preparation, pharmaceutical compositions comprising them and uses thereof in the manufacture of medicaments
CA2582512A1 (en) Compounds, compositions containing them, preparations thereof and uses thereof ii
US20030109549A1 (en) 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists
EP2464646B1 (en) Process for the preparation of cathepsin s inhibitors
KR20110075017A (ko) Nk3 수용체 길항제로서 퀴나졸린 유도체
JPWO2006080519A1 (ja) ジアミン誘導体
WO2000031061A1 (fr) Derives de 2-oxo-imidazole
MXPA00007051A (en) 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists
MXPA01001331A (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
MXPA01000116A (en) Benzimidazole compounds as orl1-receptor agonists
MXPA99009765A (en) 1,3,8-triazaspiro[4.5]decanone compound as orl1-receptor agonist